Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-08

Clinical Trial Update: Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial results for RPC1063 in moderate to severe Crohn's disease have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RPC1063 (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-10-08